Shanghai-based StairMed Technology has closed a 500 million yuan (roughly $72.7 million) strategic financing round led by Alibaba Group, with state-backed SDIC Unity Capital co-investing. Existing shareholders including Tencent, OrbiMed, Qiming Venture Partners, Lilly Asia Ventures, Source Code Capital, and FountainBridge Capital all followed on. The deal pushes StairMed’s cumulative fundraising past 1.1 billion yuan — approximately $160 million — in the space of a single year, making it the best-capitalised pure-play invasive BCI company in China.
The round marks the first direct brain-computer interface investment for both Alibaba and Tencent. Their simultaneous arrival signals that China’s largest consumer-internet platforms now view BCI as a credible next-generation human-computer interaction layer, not a distant academic curiosity.
Ultra-flexible electrodes and a surgical robot
StairMed was founded in 2021 by Li Xue, a returnee engineer with degrees from the University of Texas at Austin and Rice University, alongside co-founder and chief scientist Zhao Zhengtuo. The company builds penetrating-electrode arrays — the same broad category as Neuralink’s N1 implant — but emphasises ultra-flexible electrodes it says measure one-hundredth the thickness of a human hair, designed to reduce the chronic inflammatory response that degrades signal quality over time.
In December 2025 StairMed unveiled its second-generation system, the WRS02, a wireless 256-channel implant it describes as the world’s smallest wireless invasive BCI. The device is paired with a proprietary surgical robot that handles electrode insertion. By early 2026 the company had completed its first clinical implantation using the full stack — robot, implant, and decoder software — and verified brain-controlled interaction in a human patient.
Path to registration trials
StairMed received “green channel” fast-track status from China’s National Medical Products Administration, the same accelerated regulatory pathway that just delivered the world’s first commercial BCI clearance to rival Neuracle Medical Technology. The company plans to begin multicenter registration trials later this year, aiming to enrol and implant roughly forty patients before the end of 2026.
That timeline is aggressive but not unreheard-of in China’s current regulatory climate. The NMPA has been actively cultivating the sector, and just this month the National Healthcare Security Administration designated BCI procedures as independently billable medical services — a prerequisite for hospital adoption and insurance coverage.
Competitive context
The funding lands days after Neuracle’s landmark commercial clearance and weeks after Gestala, an ultrasound-focused BCI startup backed by Shanda Interactive founder Tianqiao Chen, raised 150 million yuan with participation from Gobi Ventures and Dalton Venture. Together the three rounds represent more than $300 million flowing into Chinese BCI companies in early 2026 alone.
Internationally, Neuralink has implanted twelve patients and is scaling toward mass production, while OpenAI-backed Merge Labs raised $252 million for its own ultrasound-based approach. StairMed’s combination of heavyweight strategic backers, a working 256-channel prototype, and a clear regulatory pathway to registration trials makes it the Chinese entrant most directly comparable to Neuralink in both technology and ambition.